… -line treatment of small-cell lung cancer: a phase II study in patients with refractory and
sensitive disease. The European Organization for Research and Treatment of Cancer Early …

… Although newer treatments are being incorporated in the … patients with relapsed small-cell
lung cancer (SCLC), underscoring … treatment options and recent progress made in the first-line …

… -/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer to
be … testing, the treatment of first-line, and second-line/third-line therapy in metastatic NSCLC …

… to the use of chemotherapy plus PD-(L)1 inhibitors will not persist indefinitely, and we will
ultimately be able to direct optimal first-line therapy based on tumor and patient features. …

… line chemotherapy for advanced non-small cell lung cancer… line in patients not suitable or
intolerant to chemotherapy, and in all patients as third-line treatment after failure of second-line …

… -cell lung cancer (NSCLC) is the leading cause of cancer mortality in Canada. Although
treatment … paradigm shifts in the approach to treatment, they are steadily improving. Customizing …

… Phase III trials assessing outcome in both histologies of an immune checkpoint inhibitor as
monotherapy in the first-line setting in non–small-cell lung cancer. NOTE. All data presented …

… This article reviews the growing evidence for first-line treatment in NSCLC. … -small cell lung
cancer (NSCLC) present with metastatic disease, and the majority of the patients treated with …

… small-cell lung cancer (SCLC) were treated with VP-16 and cisplatin as first-line therapy. In
… , Columbus, Ohio) containing regimen was contraindicated because of severe cardiac or …

… Consensus Conference on Lung Cancer was held … -cell lung cancer (NSCLC) in each of
four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment …